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Abstract
The entry of the SARS coronavirus (SCV) into cells is initiated by binding of its spike envelope
glycoprotein (S) to a receptor, ACE2. We and others identified the receptor-binding domain (RBD)
by using S fragments of various lengths but all including the amino acid residue 318 and two other
potential glycosylation sites. To further characterize the role of glycosylation and identify residues
important for its function as an interacting partner of ACE2, we have cloned, expressed and
characterized various soluble fragments of S containing RBD, and mutated all potential glycosylation
sites and 32 other residues. The shortest of these fragments still able to bind the receptor ACE2
did not include residue 318 (which is a potential glycosylation site), but started at residue 319, and
has only two potential glycosylation sites (residues 330 and 357). Mutation of each of these sites
to either alanine or glutamine, as well as mutation of residue 318 to alanine in longer fragments
resulted in the same decrease of molecular weight (by approximately 3 kDa) suggesting that all
glycosylation sites are functional. Simultaneous mutation of all glycosylation sites resulted in lack of
expression suggesting that at least one glycosylation site (any of the three) is required for
expression. Glycosylation did not affect binding to ACE2. Alanine scanning mutagenesis of the
fragment S319–518 resulted in the identification of ten residues (K390, R426, D429, T431, I455,
N473, F483, Q492, Y494, R495) that significantly reduced binding to ACE2, and one residue (D393)
that appears to increase binding. Mutation of residue T431 reduced binding by about 2-fold, and
mutation of the other eight residues – by more than 10-fold. Analysis of these data and the mapping
of these mutations on the recently determined crystal structure of a fragment containing the RBD
complexed to ACE2 (Li, F, Li, W, Farzan, M, and Harrison, S. C., submitted) suggested the existence
of two hot spots on the S RBD surface, R426 and N473, which are likely to contribute significant
portion of the binding energy. The finding that most of the mutations (23 out of 34 including
glycosylation sites) do not affect the RBD binding function indicates possible mechanisms for
evasion of immune responses.
Background
Viral envelope glycoproteins initiate entry of viruses into
cells by binding to cell surface receptors followed by con-
formational changes leading to membrane fusion and
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delivery of the genome to the cytoplasm [1]. The spike (S)
glycoproteins of coronaviruses are no exception and
mediate binding to host cells followed by membrane
fusion; they are major targets for neutralizing antibodies
and form the characteristic corona of large, distinctive
spikes in the viral envelopes [2,3]. Such 20 nm complex
surface projections also surround the periphery of the SCV
particles [4]. The level of overall sequence similarity
between the predicted amino acid sequence of the SCV S
glycoprotein and the S glycoproteins of other coronavi-
ruses is low (20–27% pairwise amino acid identity) except
for some conserved sequences in the S2 subunit [5]. The
low level of sequence similarity precludes definite conclu-
sions about functional and structural similarity.
The full-length SCV S glycoprotein and various soluble
fragments have been recently cloned, expressed and char-
acterized [6-11]. The S glycoprotein runs at about 170–
200 kDa in SDS gels suggesting posttranslational modifi-
cations as predicted by previous computer analysis and
observed for other coronaviruses [6,11]. S and its soluble
ectodomain, Se, were not cleaved to any significant degree
[6]. Because the S protein of coronaviruses is a class I
fusion protein [12], this observation classifies the SCV S
protein as an exception to the rule that class I fusion pro-
teins are cleaved exposing an N-terminal fusogenic
sequence (fusion peptide) although cleavage of S could
enhance fusion [9].
Because S is not cleaved, it is difficult to define the exact
location of the boundary between S1 and S2; presumably
it is somewhere between residues around 672 and 758
[6,7]. Fragments containing the N-terminal amino acid
residues 17 to 537 and 272 to 537 but not 17 to 276
bound specifically to Vero E6 cells and purified soluble
receptor (ACE2) molecules [6]. Together with data for
inhibition of binding by antibodies, developed against
peptides from S, these findings suggested that the recep-
tor-binding domain (RBD) is located between amino acid
residues 303 and 537 [6]. Two other groups obtained sim-
ilar results and found that independently folded frag-
ments containing residues 318 to 510 [8] and 270 to 510
[10] can bind receptor molecules. Currently, these frag-
ments are being further characterized to better understand
the interactions of the virus with its receptor as well as
their potential as inhibitors of the virus entry by blocking
these interactions. Here, we present evidence that glyco-
sylation of these and other fragments containing the S
RBD does not affect to any measurable degree their bind-
ing to the receptor (ACE2), and analyze the S RBD-ACE2
interaction.
Results
A short RBD fragment containing only two potential 
glycosylation sites folds independently and binds ACE2
We and others have previously identified the RBD by
using fragments containing three potential glycosylation
sites – at residues 318, 330 and 357 [6,8,10]. To find the
Expression and binding of soluble S fragments containing the RBD Figure 1
Expression and binding of soluble S fragments containing the RBD. A) Soluble S proteins concentrated using Ni-NTA 
agarose beads from the supernatants of 293 cells transfected with various constructs were run, blotted onto a nitrocellulose 
membrane and detected with anti-c-myc epitope antibody. B) Cell binding assay data using supernatants described above, 
shown as a percentage of the reading of S272–537 that has been used in this experiment as a positive control.
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minimal number of potential glycosylation sites and
shortest length required for expression and folding of S
RBD fragments, we cloned in pSecTag 2B fragments with
various number of potential glycosylation sites and length
including S317–518, S319–518, S329–518, S364–537,
S399–518, S317–493, and S329–458, where the numbers
after S denote the amino acid residues confining the frag-
ment. Note that these fragments were not constructed as
fusion proteins with Fc as in a previous report [8]. This is
why we also designed and tested several fragments with
deleted portions of the RBD that have already been shown
to be important for binding to ACE2 including regions
between residues 327 and 490 [8]. The S317–518 and
S319–518 fragments were secreted in the culture superna-
tant (Fig 1A), and bound to ACE2-expressing cells (Fig 1B)
and purified ACE2 (Table 1 and data not shown). The dif-
ference in the molecular weights of the two fragments
(about 3 kD) is much larger than the calculated weight
due to the two additional amino acids contained in S317–
518, and is likely due to glycosylation. Both fragments
bound to ACE2 at comparable levels (Fig. 1B). The other
fragments were not secreted (Fig. 1A) but could be
detected by Western in cell lysates (data not shown).
These results suggest that a short fragment (S319–518),
which is not a fusion protein, with only two glycosylation
sites can be independently folded and secreted in a solu-
ble form, and can bind ACE2.
The potential glycosylation sites in RBD fragments are 
functional and glycosylation does not affect binding to 
ACE2
To find whether the potential glycosylation sites in the
RBD fragments are functional we constructed mutants,
where the three residues N318, N330 and N357 in S317–
319 were mutated individually from asparagine to
alanine. As is shown in Fig. 2A all three mutants were
expressed and ran on SDS-PAGE at molecular weights of
about 3 kD smaller than the unmodified fragment. They
all bound to ACE2 (Fig. 2B). Similar results were obtained
with the shorter fragment (S319–518) where asparagines
were also mutated to glutamines, which better mimic
asparagines (Fig. 3). These results suggest that all glyco-
sylation sites in the RBD are functional, and that the lack
of glycosylation in any of the glycosylation sites does not
interfere with binding to ACE2.
Only one glycosylation site is required for secretion of 
functional RBD fragments
To find the minimal number of functional glycosylation
sites required for secretion of the RBD we generated dou-
ble mutants of S319–518 where the asparagines N330
and N357 were mutated to either alanines (Ala 2) or
glutamines (Gln 2). These mutants were not detected in
the culture supernatants (Fig. 4A) and the culture superna-
tants did not exhibit any binding activity to ACE2 (Fig.
4B). These results suggest that at least one glycosylation
site is required for secretion of functional RBD fragments.
Identification of 11 RBD amino acid residue mutations 
that affect its binding to ACE2, and 20 – that do not
To identify RBD amino acid residues that might affect
binding to ACE2, we converted 32 residues in S319–518
to alanine, expressed the mutants and tested their binding
to ACE2. Eleven mutants, K390, R426, D429, T431,
D454, I455, N473, F483, Q492, Y494, and R495 exhib-
ited decreased binding to ACE2 at comparable levels of
Table 1: S RBD mutants, expression levels and binding to ACE2.
Mutant Mutation Expression Binding ASA
1 E327 98 83 123
2K 3 3 3 8 6 9 0 1 7 6
3* K344 95 102 159
4 K390 104 1 44
5 D392 110 95 69
6 D393 30 100 10
7K 4 1 1 9 0 1 0 3 3 3
8 D414 120 130 113
9 D415 90 102 97
10* R426 73 7 95
11 N427 100 111 121
12 D429 103 0 9
13 T431 131 64 59
14 K439 85 87 65
15 R441 10 15 3
16* Y442 105 110 68
17* R444 80 86 52
18 H445 124 103 113
19 K447 87 85 138
20 R449 96 101 178
21 F451 69 71 64
22 D454 50 4 25
23 I455 77 6 89
24 D463 87 81 70
25* L472 95 99 172
26 N473 100 0 70
27 W476 80 76 126
28 F483 91 3 2
29 Q492 95 3 5
30 Y494 50 7 21
31 R495 97 19 7
32 E502 110 84 175
33 S17–276 90 0
34 S319–518 100 100
The mutants that significantly decrease binding to ACE2 are shown in 
bold. The * denotes mutant residues that are naturally occurring in 
various SCV strains (see Fig. 6A). The binding and expression values 
for the individual mutants are expressed as a percentage of the value 
for the S319–518 (wt) that is assumed 100%. The values of accessible 
surface area (ASA, Å2) for mutant residues were calculated from the 
crystal structure of the S RBD-ACE2 complex (coordinates provided 
by S. Harrison) by using the Lee and Richards' algorithm [23] with a 
probe radius of 1.4 Å.Virology Journal 2005, 2:73 http://www.virologyj.com/content/2/1/73
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expression (Table 1). Note that RBD fragment mutated at
D454 or Y494 was expressed at somewhat lower levels but
binding was much more significantly reduced. In addi-
tion, one of these mutations, D454, was previously shown
to affect the RBD-ACE2 interaction [8]. The T431 muta-
tion reduced binding but to lesser extent than the other
Glycosylation of S fragment containing the RBD Figure 2
Glycosylation of S fragment containing the RBD. A) Expression of the three mutants on S317–518 where the potential 
sites of glycosylation at N318, N330 and N357 were individually converted to alanine. All the mutants appear to have similar 
molecular weights when compared to the wild type protein S317–518. B) Cell binding data of the same mutants.
Effects of glycosylation on expression and binding of RBD-containing fragments Figure 3
Effects of glycosylation on expression and binding of RBD-containing fragments. A) Expression of the four mutants 
on S319–518 where the two sites of glycosylation at N330 and N357 have been individually converted to either alanine or 
glutamine. The various mutants have similar molecular weights, a little less than the wild type indicating that the level of glyco-
sylation at each residue might be similar. B) Cell binding data for the same mutants.
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mutations that decreased very significantly (more than
10-fold) the RBD-ACE2 interaction. The protein mutated
at R441 expressed poorly and we were not able to assess
its role in the RBD binding, although because of the sim-
ilar levels of decrease in binding and expression, it is likely
that this mutation does not affect binding. Interestingly, it
appears that the D393 mutation enhanced binding – the
mutated fragment expressed at low concentration but its
binding equaled the binding of the non-mutated protein.
The mutated residues that affect RBD binding include
positively and negatively charged, polar and hydrophobic
residues, indicating a role of electrostatic and hydropho-
bic interactions in the RBD-ACE2 interactions. These
results also demonstrate that the mutations for the
selected panel of residues that do affect binding are signif-
icantly (about 2-fold) more than those that do not, sug-
gesting possible mechanisms of immune evasion.
Analysis of the S RBD sequence and the role of critical 
residues in S RBD
In order to further characterize the RBD and its interaction
with ACE2 we analyzed the sequence and secondary struc-
ture, and how they relate to the mutations that affect
binding to the receptor. A sequence-based secondary
structure analysis of the S RBD predicted mostly β-sheets
(data not shown), connected by loops or turns, where
most of the residues affecting the RBD-ACE2 interactions
are located. To find out additional residues that are not
likely to affect binding significantly we aligned multiple
RBD sequences of various non-redundant SCV strains.
Figure 5A shows the identified 13 amino acid residues,
which can be mutated without affecting the function of
the virus to cause infection. Interestingly, one of these res-
idues, R426, which decreases binding to ACE2 about 10-
fold if mutated to A, is mutated to G in one of the strains.
Four of the other 12 mutations (indicated with * in Table
1) do not affect binding to ACE2 when converted to A. To
examine the extent of similarities of the SCV RBD
sequence with related sequences of other coronaviruses
from different organisms, which share only about 20–
35% sequence identities, we performed multiple align-
ments using BLAST. Strikingly, six cysteine residues are
conserved (Fig. 5B) indicating the possibility for up to
three possible disulphide bridges within the S RBD that
can help to keep the structural integrity of this domain.
Most of the residues we found important for binding are
highly variable except T431, Q492 and R495, which are
highly conserved (Fig. 5B). The multiple sequence align-
ment score was then used to build a phylogram by using
the ClustalW software. The results suggested that the SCV
S RBD is much more distant than the respective regions of
the other tested coronaviruses (Fig. 5C).
Recently, the crystal structure of S RBD-ACE2 complex was
solved and the coordinates became available after the
completion of this study, kindly provided by Stephen
Harrison (Li, F, Li, W, Farzan, M, and Harrison, S. C., sub-
mitted). We have mapped the S RBD mutations on the
surface of the crystal structure by using InsightII software.
The Connolly molecular surface of the S RBD as viewed
Glycosylation of at least one residue in RBD-containing fragments is required for expression Figure 4
Glycosylation of at least one residue in RBD-containing fragments is required for expression. A) Expression pat-
tern of two mutants on S319–518 in which both the glycosylation sites at N330 and N357 have been mutated either to alanine 
or to glutamine. No expression is seen when both the sites have been mutated indicating that glycosylation of at least one of 
the sites is important. In the last lane, purified S317–518 protein has been loaded as a control. B) Cell binding results of the 
same mutants.
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from the receptor ACE2 is shown in Fig. 6A. The S RBD is
in yellow color in which the mutants that significantly
affect the binding to ACE2 are shown in red and those that
do not affect the binding are in cyan. The two glycosyla-
tion sites at 330 and 357 positions are colored in green. In
the right panel the structure is rotated by 180° to show the
opposite side of the RBD surface.
In the structure of the S RBD-ACE2 complex two of the
mutants with very significantly reduced binding to ACE2,
R426A and N473A, make contacts with ACE2 residues
and are completely exposed (Table 1). They are separated
by residues whose mutations do not affect the S RBD
binding to ACE2. Interestingly, six of the mutations we
identified to reduce binding are buried but at close prox-
imity to R426 as shown by the translucent surface high-
lighting in Fig. 6B indicating sensitivity of this area to
mutations and likely involvement of other residues. Resi-
dues D454 and I455, whose mutation reduced binding to
ACE2, do not make contacts with ACE2 and are located on
Multiple sequence alignment of S fragment (RBD) with SARS CoV-related and other coronaviruses/spike glycoproteins Figure 5
Multiple sequence alignment of S fragment (RBD) with SARS CoV-related and other coronaviruses/spike glyc-
oproteins. A) The table shows 13 amino acid residues in the region of S RBD (319–518) which have sequence variations as 
identified from the multiple sequence alignment of S RBD with 19 SARS CoV-related sequences (97–99% identities with S 
RBD) using BLAST. B) Multiple sequence alignment of S RBD and 7 other related proteins from different organisms which 
share 20–35% identities: bovine coronavirus (BCoV, 327–622), canine respiratory coronavirus (CCoV, 327–622), human coro-
navirus (OC43, 331–612), equine coronavirus (ECoV, 327–622), porcine hemagglutinating encephalomyelitis virus (PHEV, 327–
608), rat sialodacryoadenitis coronavirus (RtCoV, 325–610) and murine hepatitis virus (MHV, 325–611). Dark and gray colors 
indicate the identity and similarity of residues aligned. Arrowheads on the S RBD sequence show the 13 sites, which are found 
to have sequence variations. C) The phylogram tree is shown with distances along the protein names and note that S RBD has 
the highest distance. Multiple sequence alignment and phylogram were constructed using ClustalW program.
Residue Mutation (times)
R342 G(1)
K344 R(9)
F360 S(7)
R426 G(1)
S432 P(1)
N437 D(1)
Y442 S(1)
R444 K(1)
L472 P(7)
N479 S(6), R(3), K(1)
D480 G(7)
T487 S(7)
F501 Y(1)
^^ ^
^^ ^ ^ ^
^^ ^ ^
^
AB
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the side opposing the side facing the receptor (right panel
of Fig. 6); it is likely that the mutations decrease binding
by inducing conformational changes. Other mutations
including mutations of the two glycosylations sites on
that side do not affect binding to ACE2 (right panels of
Fig. 6). These results suggest the existence of two hot spots
on the S RBD surface, R426 and N473, which are likely to
contribute significant portion of the binding energy.
Discussion
The major results of this work are the demonstration of
the functionality of the potential glycosylation sites of the
S RBD and the requirement of at least one of them for its
proper expression as well as the identification of two hot
spots on the S RBD surface, R426 and N473, which are
likely to contribute significant portion of the binding
energy to ACE2. ACE2 was previously identified as a
receptor for the SCV [7] and this finding was confirmed
[6,13]. ACE2 binds with high (nM) affinity to S and is
Mapping of the S RBD mutants on the structure Figure 6
Mapping of the S RBD mutants on the structure. The molecular surface diagrams of S RBD are shown as the top views 
in the solid and translucent models. The S RBD surface is in yellow, mutations that significantly affect the binding to ACE2 are 
in red and those do not affect the binding in cyan. (A) Shown are the solid surface diagrams using the structure of S RBD (left 
panel) and related by 180° rotations (right panel). The residues that decrease the receptor binding as observed in the experi-
ment and exposed in the structure are labeled (R426, N473). (B) The same surface diagrams as in A but with transparency 
which are related by 180° rotations. The buried residues, which reduce the receptor binding as observed in the experiment, 
are seen as blurred red.
R426
N473
(A1) (A2)
(B1)
D454, I455
180°
R426
N473
(B2)
180°
D454, I455
buried residuesVirology Journal 2005, 2:73 http://www.virologyj.com/content/2/1/73
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expected to induce conformational changes required for
membrane fusion [6-8,14]. Its crystal structure was
recently reported [15] and is in general agreement with
two homology models previously developed [16,17]. It
was proposed that the S binding domain on ACE2
involves residues on the ridges surrounding the enzymatic
site [17]. Recently, several ACE2 regions and amino acid
residues were identified as important for its binding to the
S RBD [18].
Currently, the three-dimensional (3D) structure of the S
RBD in free unbound form is unknown. We performed
sequence analysis and developed a 3D model of a frag-
ment containing the S RBD (the model will be described
elsewhere). According to this model the S RBD like RBDs
from other viruses contains predominantly β-sheets. Most
of the residues affecting the ACE2 interactions are exposed
on the surface of the beta sheets and inter-connecting
loops. These predicted observations are consistent with
the recently solved crystal structure of S RBD complexed
with ACE2 (Li, F, Li, W, Farzan, M, and Harrison, S. C.,
submitted). The nature of the residues, which include
charged, hydrophobic and polar residues indicated that
all these types of interactions could be involved either
directly or indirectly in the S RBD binding to ACE2. Nota-
ble are the complementarities in the charges of several res-
idues in S, e.g. R426 and N473 with those of ACE2, e.g.
E329 and Q24, respectively. One can reason that these res-
idues might contribute significantly for the on rate
constant and proper orientation of the two molecules in
the complex, as well as to the low dissociation rate con-
stant. We identified two hot spots, residues R426 and
N473, which are likely to contribute to the bulk of the free
energy of interaction. Further studies are required for the
elucidation of the energy profile of the S RBD-ACE2
interaction.
We found that not only glycosylation of the three sites in
the previously described RBD-containing fragments is dis-
pensable for expression (except one that can be any) but
it also does not affect binding to ACE2. Indeed all glyco-
sylation sites are localized at the N-terminal portion of the
RBD and are relatively close to each other not only in the
sequence (residues 318, 330 and 357) but also in the 3D
space (Fig. 6). We constructed a fragment (319–518),
which contains only two glycosylation sites and still binds
with an affinity undistinguishable from the fragments
containing three glycosylation sites. Further mutations of
all combinations of these sites revealed that only one of
them is required for expression but none of them for
binding. Therefore the S RBD contacts ACE2 by an area
lacking carbohydrates, which is in agreement with the
recently solved crystal structure of the S RBD (Li, F, Li, W,
Farzan, M, and Harrison, S. C., submitted).
The entry of the SCV into cells can be inhibited by anti-
bodies that bind the S glycoprotein and prevent its bind-
ing to ACE2. Such a monoclonal antibody that potently
inhibits membrane fusion at nM concentrations was
recently identified by screening phage display libraries
[19]. This antibody competed with ACE2 for binding to
the S glycoprotein suggesting that its mechanism of neu-
tralization involves inhibition of the virus-receptor inter-
action. We have also identified several antibodies specific
for the S RBD ([20] and Zhu and Dimitrov, in
preparation). The mutants developed in this study could
be useful for mapping the epitopes of the antibodies
against the S RBD, most of which are likely to neutralize
the virus by preventing binding to the receptor ACE2.
Most of the mutations (20) described in this study did not
affect binding of the S RBD to ACE2. This finding suggests
that the virus could easily mutate and escape antibodies
that do not exhibit the same energy profile of binding to
S as ACE2. However, further studies are required in the
context of the whole oligomeric S protein to make more
definite conclusions about possible mechanisms of
immune evasion.
The results reported in this study could have implications
for understanding the mechanisms of SCV entry, and for
development of entry inhibitors, vaccine immunogens,
and research tools. Future studies particularly the solution
of the crystal structure of the S protein in free unbound
form, and in complex with ACE2, as well as measure-
ments of the energy profiles of binding to ACE2 and anti-
bodies, could elucidate detailed mechanisms of the S RBD
function that may help in the further development of clin-
ically useful inhibitors and vaccines.
Methods
Plasmids and antibodies
Plasmid encoding the soluble form of ACE2, pCDNA3-
ACE2-ecto, was kindly provided by M. Farzan from Har-
vard Medical School, Boston, Massachusetts. VTF7.3 is a
kind gift from C. Broder, USUHS, Bethesda, MD. Expres-
sion vectors pSecTag2 series were purchased from Invitro-
gen (Carlsbad, California). The monoclonal anti-c-Myc
epitope antibodies (unconjugated and conjugated to
HRP) were obtained from Invitrogen (Carlsbad, CA).
Cloning of S fragments
Using the previously described S756 [6] plasmid as tem-
plate, fragments S364–537 (5'-GATCGGATCCTCAAC-
CTTT AAGTGC-3' and 5'-GATCGAATTCC AGTAC
CAGTGAG-3'), S317–518 (5'-GATCGGATCCCCTAATAT-
TACAAAC-3' and 5'-G ATCGAATTCGGTCAGTGG-3'),
S317–471 (5'-GATCGGATCC CCTAATATTAC AAAC-3'
and 5'-GATCGAATTCGAGCAGGTGGG-3'), S329–518
(5'-GATCGGA TCCTTCCC TTCTGTC-3' and 5'-GATC-Virology Journal 2005, 2:73 http://www.virologyj.com/content/2/1/73
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GAATTCG GTCAGTGG-3'), S329–458 (5'-GATC GGATC-
CTTCCCTTCTGTC-3' and 5'-
GATCGAATTCGCACATTAGA TATGTC-3'), S319–518 (5'-
GATCGGATCCA TTACAAACTTGTGTCC-3' and 5'-GATC-
GAATTCG GTCAGTGG-3'), S399–518 (5'-GATCGGATC-
CCCAGG ACAA ACTGG-3' and 5'-GA TCGAAT
TCGGTCAGTGG-3'), and S317–493 (5'-GATCG GATC-
CCCTAATATTACA AAC-3' and 5'-GATCGAATTCAAGG
TTGGTAGCC-3') were PCR amplified using the primers
mentioned within the parentheses. The PCR amplified
fragments were then directionally cloned into expression
vector pSecTag 2B using the restriction enzymes Bam HI
and Eco RI. The various mutations on S317–518 and
S319–518 were generated using the QuickChange® XL Site
Directed Mutagenesis kit (Stratagene, La Jolla, CA) follow-
ing the manufacturer's protocol.
Protein expression
Various plasmids were transfected into 293 cells using the
Polyfect transfection kit from Qiagen (Valencia, CA) fol-
lowing the manufacturer's protocol. Four hours after
transfection, cells were infected with VTF7.3 recombinant
vaccinia virus encoding the gene for the T7 polymerase.
The soluble S fragments were obtained from the cell cul-
ture medium.
Western blotting
Loading buffer and DTT (final concentration 50 mM)
were added to either S proteins concentrated from the cul-
ture supernatant using Ni-NTA agarose beads or directly
to the supernatant, boiled and run on an SDS-PAGE. The
monoclonal anti-c-Myc epitope antibody (Invitrogen,
Carlsbad, CA) was diluted in TBST buffer and incubated
with the membrane for 2 hours, washed and then incu-
bated with the secondary antibody conjugated with HRP
for 1 hour, washed four times, each time for 15 min, and
then developed using the ECL reagent (Pierce, Rockford,
IL).
Cell binding assay
Medium containing soluble S fragments was collected and
cleared by centrifugation. Vero E6 cells (5 × 106) were
incubated with 0.5 ml of cleared medium containing sol-
uble S fragments and 2 µg of anti-c-Myc epitope antibody
conjugated with HRP at 4°C for two hours. Cells were
then washed three times with ice cold PBS and collected
by centrifugation. The cell pellets were incubated with
ABTS substrate from Roche (Indianapolis, IN) at RT for 10
min., the substrate was cleared by centrifugation, and
OD405 was measured.
ELISA
For the detection of the S protein fragments, a sandwich
ELISA was used in which the plate was coated with anti-
His tag antibody. The S protein containing culture
supernatants were added and detected with an anti-c-Myc
epitope antibody. In the second ELISA, the S protein was
bound to the C9-tagged ecto-domain of receptor ACE 2
that was captured on a plate coated with anti-C9 antibody
(ID4). As in the previous ELISA, the S protein was detected
with anti-c-myc epitope antibody. The second ELISA was
used to score the binding of the various S protein frag-
ments to the receptor ACE 2. In all experiments, the incu-
bations with the c-myc epitope antibody were for 2 h at
RT.
Sequence analysis of S RBD
Sequence similarity searches were performed using NCBI
BLAST program [21] by selecting, separately, all non-
redundant sequences (nr) and sequences derived from the
3-dimensional structure records from the Protein Data
Bank (PDB). The BLAST analysis against nr database
showed 19 SARS CoV-related sequences from different
clones with identities of 97–99% from the top of the list
as well as 7 different coronaviruses from other organisms
which share only 20–35% sequence identities at the bot-
tom. These sequences were collected and aligned with the
sequence of SARS RBD fragment using ClustalW program
[22] with default parameters. The multiple alignment
sequence table was prepared by choosing the aligned
sequences with optimal gaps and then a phylogram tree
was constructed based on that alignment scores for the 7
different coronaviruses along with S RBD. Further, the
BLAST against PDB database retrieved 5 hits and 4 of them
have longer stretch of amino acids (PDB codes: 1KS5,
1K0H, 1NKG and 1QR0), which have detectable sequence
similarities with different regions of SARS RBD.
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